Standout Papers
- Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation (2005)
- Sclerostin Is an Osteocyte-expressed Negative Regulator of Bone Formation, But Not a Classical BMP Antagonist (2004)
- 10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension (2017)
- Bone Morphogenetic Proteins Stimulate Angiogenesis through Osteoblast-Derived Vascular Endothelial Growth Factor A (2002)
Immediate Impact
5 by Nobel laureates 4 from Science/Nature 91 standout
Citing Papers
Postmenopausal Osteoporosis
2023 Standout
Osteoporosis
2019 Standout
Works of Socrates E. Papapoulos being referenced
10 years of denosumab treatment in postmenopausal women with osteoporosis: results from the phase 3 randomised FREEDOM trial and open-label extension
2017 Standout
The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study
2015
Author Peers
| Author | Last Decade | Papers | Cites | |||
|---|---|---|---|---|---|---|
| Socrates E. Papapoulos | 9000 | 7171 | 7164 | 298 | 17.2k | |
| H. Fleisch | 10380 | 5408 | 6175 | 300 | 19.1k | |
| Lorenz C. Hofbauer | 9417 | 7948 | 13065 | 427 | 24.0k | |
| Paul D. Miller | 10095 | 12153 | 5831 | 246 | 17.7k | |
| T. John Martin | 9165 | 3107 | 10220 | 260 | 17.6k | |
| Lawrence G. Raisz | 8001 | 5740 | 10050 | 361 | 23.3k | |
| Brendan F. Boyce | 10342 | 4859 | 14257 | 197 | 24.4k | |
| Gideon A. Rodan | 10693 | 6321 | 14447 | 255 | 25.9k | |
| Erik Fink Eriksen | 9207 | 12313 | 7952 | 257 | 21.2k | |
| David L. Lacey | 11110 | 5269 | 15761 | 101 | 23.4k | |
| Michael R. McClung | 11915 | 15835 | 8648 | 273 | 22.1k |
All Works
Login with ORCID to disown or claim papers
Loading papers...